Enzyme targets sepsis; International team tests new cancer drug delivery tech; Chance vs. lifestyle: Which is most likely to cause cancer?;

> A new study indicates that a human membrane-bound enzyme called CD39 could target an "Achilles heel" for sepsis. Release

> A research team drawn from North Carolina and China has used graphene strips to deliver cancer drugs to specific areas of a cell. They tested the tech in animal models for lung cancer. Release

> Chance mutations are responsible for the lion's share of new cancer cases, according to new research. Lifestyle matters like smoking are far less likely to cause cancer than chance. Story

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.